GEMINA LABS LTD (8I7) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GEMINA LABS LTD (8I7) has a cash flow conversion efficiency ratio of -0.007x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€34.61K ≈ $40.46K USD) by net assets (€-5.14 Million ≈ $-6.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GEMINA LABS LTD (8I7) liquidity interval to measure how many days the company can operate on defensive assets alone.
GEMINA LABS LTD - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how GEMINA LABS LTD's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GEMINA LABS LTD Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GEMINA LABS LTD ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mercia Technologies PLC
LSE:MERC
|
0.032x |
|
ZyVersa Therapeutics Inc.
NASDAQ:ZVSA
|
119.987x |
|
CanadaBis Capital Inc
V:CANB
|
0.056x |
|
MT Educare Limited
NSE:MTEDUCARE
|
-0.407x |
|
Oakridge International Ltd
AU:OAK
|
-0.447x |
|
Ngenic AB
ST:NGENIC
|
0.592x |
|
Springfield Properties Plc
LSE:SPR
|
-0.100x |
|
Strategic Equity Capital Closed Fund
LSE:SEC
|
0.001x |
Annual Cash Flow Conversion Efficiency for GEMINA LABS LTD (2022–2025)
The table below shows the annual cash flow conversion efficiency of GEMINA LABS LTD from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see 8I7 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-01-31 | €-4.44 Million ≈ $-5.19 Million |
€-1.30 Million ≈ $-1.52 Million |
0.293x | -85.66% |
| 2024-01-31 | €-1.59 Million ≈ $-1.85 Million |
€-3.24 Million ≈ $-3.79 Million |
2.046x | -96.74% |
| 2023-01-31 | €-71.81K ≈ $-83.95K |
€-4.51 Million ≈ $-5.27 Million |
62.798x | +1631.50% |
| 2022-01-31 | €944.23K ≈ $1.10 Million |
€-3.87 Million ≈ $-4.53 Million |
-4.100x | -- |
About GEMINA LABS LTD
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporat… Read more